Investment Thesis — Zoetis Inc.
Zoetis is mispriced because the market extrapolates recent underperformance as structural decline, ignoring the resilience and secular growth in animal health and pet care. The Street is missing the inflection point where veterinary demand rebounds, and Zoetis' pricing power and pipeline drive earnings acceleration.
Catalysts
- Veterinary demand rebound
- Successful launch of new biologics
- Margin expansion from premium products
Risk Factors
- Sustained weakness in pet care spending
- Regulatory pricing pressure
- Pipeline execution failures
Key Debates
ZTS re-rates to 19x P/E by Q4, reaching PT.
Zoetis's revenue growth accelerates above 5.5% by Q3.
ZTS short squeeze drives 10% rebound by Q4.